Quality of life (QoL) analysis from ENSURE, a phase 3, open-label study of first-line erlotinib versus gemcitabine/cisplatin (gp) in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive (mut+) non-small-cell lung cancer (NSCLC)
Y. Wu
Quality of life (QoL) analysis from ENSURE, a phase 3, open-label study of first-line erlotinib versus gemcitabine/cisplatin (gp) in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive (mut+) non-small-cell lung cancer (NSCLC)
Y. Wu